Marinos Tsiatas

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano et al. · The Lancet Oncology · 2020 · 485 citations · Full text

Surgical Oncology, Urology, Metastatic Urothelial Carcinoma +8

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals <i>via</i> VEGF receptor Type 2

Apostolos C Ziogas, Nikos G. Gavalas, Marinos Tsiatas et al. · International Journal of Cancer · 2011 · 162 citations

Healthy Individuals, T-regulatory Cell, Immunology +17

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

N. Gavalas, Marinos Tsiatas, Ourania Tsitsilonis et al. · British Journal of Cancer · 2012 · 161 citations · Full text

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Aristotelis Bamias, Urania Dafni, Alexandra Karadimou et al. · Annals of Oncology · 2012 · 97 citations

Surgical Oncology, Urology, He 16/03 +7

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy

Aristotelis Bamias, Vasiliki Koutsoukou, Evangelos Terpos et al. · Gynecologic Oncology · 2007 · 92 citations

Platinum Resistance, Cancer Immunosurveillance, Malignant Disease +10